March 26, 2024 02:59 PM EDT
Pharma
FDA+

Astel­las wins ap­proval in Japan for Claudin18.2 ther­a­py af­ter US re­jec­tion

Nicole DeFeudis

Editor

Astel­las won ap­proval in Japan for Vy­loy, its gas­tric can­cer drug that was re­ject­ed by the FDA in Jan­u­ary over man­u­fac­tur­ing is­sues.

Vy­loy, al­so known …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times